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Avascular necrosisAbstract Treatment of Kienbock disease (the avascular necrosis of the lunate) is a matter of
debate. Current surgical modalities have their limitations and potential complications. Those
modalities are also not based on pathophysiology of the disease. Here we introduce a novel thera-
peutic option by combining the autologous mesenchymal stem cell injection and the core decom-
pression procedure in the treatment of Kienbock disease. We hypothesized that micro-drilling of
the lunate removes the necrotic tissue and induces new bone formation while injection of mesenchy-
mal stem cell provides a poll of multi-potent cells to replace the dead bone. This new treatment
modality would provide synergistic effects of the two therapeutic options beside lower potential
complications while eliminating the need for current surgical operations.
 2015 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The lunate is a crescent-shaped bone in the proximal carpal
row of human wrist. Avascular necrosis (AVN) of the lunate,
also known as Kienbock disease, is a multifactorial entity caus-
ing pain and restricted range of motion of the wrist [1]. As the
disease progresses, collapse and osteoarthritis of the wrist
become dominant, leading to functional loss of the joint. How-ever, prompt diagnosis and early treatment might reverse the
AVN process and restore its function [2].
Multiple surgical techniques have already been introduced
for treatment of Kienbock disease. Surgical distal radius short-
ening and ulnar lengthening aim at decompressing the lunate
by reducing the mechanical axial load to the joint. Vascular-
ized bone graft to the lunate is another surgical modality to
restore the vascular blood supply of the necrotic bone. At
the late stages of the disease, proximal row carpectomy andoo.com
S2 S.R. Mehrpour et al.wrist arthrodesis are intended to alleviate the patient’s symp-
toms. No surgical procedure has been shown to be superior
to others and the long term outcomes are still under debate
[3–5]. As the micro structural pathophysiology of the Kien-
bock disease becomes clearer, the need for more innovative
surgical treatment takes more priority.
Mesenchymal stem cells (MSCs) are un-differentiated multi-
potent cells with the ability to growth, renew and replace dam-
aged tissues in physiologic and pathologic conditions. Their
capacity to differentiate into bone, cartilage, and muscle makes
theman excellent candidate formusculoskeletal repair [6]. These
pluripotent cells could be found in almost all tissues. They are
easily isolated and successfully expanded in vitro. Their unique
homingmechanism attracts them to the site of injury where they
start secreting specific cytokines and growth factors tomodulate
neighboring cells. It has been shown that the immune-regulatory
properties of the MSCs in tissue microenvironments are their
most prominent therapeutic effect [7]. This great role is probably
responsible for recent interest toward investigating the MSC
capabilities in the treatment of wide range of acute and chronic
inflammatory and traumatic pathologies [8].
The hypothesis
Previous clinical report has already shown that core decom-
pression of the lunate would result in clinical, radiographic
and functional improvements of the patients with Kienbock
disease [9]. The proposed mechanism of the efficacy of the core
decompression technique is decreasing the intraosseous pres-
sure within the lunate leading to subsequent hyperemia. Addi-
tionally, micro-drilling within the bone removes the necrotic
tissue, inducing new bone formation thorough secretion of a
group of multifunctional cytokines [10].
We hypothesized that injection of MSCs at this stage would
provide a poll of multi-potent cells to replace the necrotic tissue
while producing a wide variety of growth factors including
bone morphogenetic proteins (BMPs), fibroblast growth factor,
insulin-like growth factor-1 and -2, transforming growth
factor-b1 (TGF-b1), platelet-derived growth factor, and vascu-
lar endothelial growth factor (VEGF) [11]. The new treatment
modality would provide synergistic effects of the two novel
therapeutic options for the treatment of Kienbock disease.
The main goal of the treatment is to restore a structural and
functional bone to resolve the patient’s symptoms by applying
minimally invasive techniques and autogenously stem cell graft.
Evaluation of the hypothesis
To evaluate the clinical efficacy of combination treatment of core
decompression and MSCs injection, a group of patients with
Kienbock disease would be recruited. Iliac bone marrow of the
patient is a suitable reservoir ofMSCs. Iliac bonemarrow aspira-
tion is generally a safe procedure taking place in an outpatient
clinic. Isolation and culture of MSC have already been described
in the literature [12]. After phenotypic and microbiological anal-
ysis, quality-assured stem cells would be ready for injection.
Core decompression surgical procedure would carry out in
an inpatient setting as described before [9]. After removing the
necrotic bone of the lunate by a drill bit, MSC injection using a
narrow catheter would take place. Patients should have short
arm cast for wrist immobilization for a period of 6 weeks.To assess the treatment outcome, subjective and objective
manifestations of the Kienbock disease should be recorded
pre and post-operatively. The questionnaire of Disabilities of
the Arm, Shoulder and Hand (DASH score) is a useful and
valid instrument for assessing the functional outcome. Wrist
range of motion also should be recorded. Radiography and
MRI are useful for longer follow-up outcomes.
Consequences of the hypothesis and discussion
This new therapeutic method aims at combining the benefits of
each treatment while minimizing their drawbacks. The first
modality, core decompression removes necrotic bone while
inducing new bone regeneration. The second modality, stem
cell injection provides a multi-potential pole of un-
differentiated cells for ultra-structure of the bone. The combi-
nation therapy could have synergistic results.
Previous therapeutic options have their own limitations.
Surgical operations with internal fixation including radius
shortening and ulnar lengthening need re-operation for device
removal several months post-operatively. Vascularized bone
graft technique is associated with donor site complications.
However, when combined with internal fixation, a second
operation is required. Allogenic MSCs have the potential risk
of infection and tissue rejection. Our new modality uses auto-
genic bone marrow aspiration with minor side effects.Overview box
First question: What do we already know about the
subject?
Kienbock disease or lunate AVN is an idiopathic disease
withmultiple introduced surgical techniques. Current treat-
ment options have their own limitations. No surgical proce-
dure has been shown to be superior to others and the long
termoutcomes are still unclear. So there is a need for further
treatmentprotocol basedonpathophysiologyof thedisease.
Second question:What does your proposed theory add to the
current knowledge available, and what benefits does it have?
Proposed treatment of core decompression and autolo-
gous stem cell injection would combine the benefits of each
treatment while minimizing their drawbacks. The first
modality, core decompression removes necrotic bone while
inducing new bone regeneration. The second modality,
stem cell injection provides a multi-potential pole of un-
differentiated cells for ultra-structure of the bone. The com-
bination therapy could have synergistic results. It needs no
internal fixation nor reoperation for device removal. It also
uses patient’s own stem cell with minimum side effects.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
A group of patients with Kienbock disease would be
recruited. The core decompression of the lunate bone and
isolation and culture of stem cells have already been intro-
duced in the literature. Iliac bone marrow aspiration is gen-
erally a safe procedure taking place in an outpatient clinic.
After phenotypic and microbiological analysis, quality-
assured stemcellswould be ready for injection.Core decom-
pression surgical procedure would carry out in an inpatient
setting. Subjective and objectivemanifestations of theKien-
bock disease should be recorded pre and post-operatively.
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